The short version of Investigational drug fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-04 and is reviewed periodically as new material appears.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
=== Natural occurrence === Hawthorn flowers have a heavy, complicated scent, the distinctive part of which is triethylamine, which is also one of the first chemicals produced by a dead human body when it begins to decay. Due to the scent, it is considered unlucky in British culture to bring hawthorn into a house. Gangrene and semen are also said to possess a similar odour.
=== Misdiagnosis === There is an ELISA-based test for brown recluse venom that can determine whether a wound is a brown recluse bite, although it is not commercially available and not in routine clinical use. Clinical diagnoses often use Occam's razor principle in diagnosing bites based on what spiders the patient likely encountered and previous similar diagnoses. Stoecker, Vetter & Dyer (2017) suggested the mnemonic "NOT RECLUSE", shown below, as a memory device to help laymen and medical professionals more objectively screen and diagnose potential cases of loxoscelism.
On 18 March, Israel struck the South Pars natural gas field in the Persian Gulf and its neighboring refineries in Iran with US coordination. In retaliation, Iran attacked the world's largest LNG production facility in Qatar, while Trump claimed he had no knowledge of the South Pars attack. Israel said it had killed Iranian intelligence minister Esmaeil Khatib in an overnight airstrike. Pezeshkian confirmed Khatib's killing. A hair salon in Beit Awwa was struck by a projectile, killing four women, with Israeli authorities stating that it was most likely cluster munitions and Palestinian authorities saying it was an errant Israeli interceptor. On 19 March, a US F-35 made an emergency landing after a suspected hit by Iranian forces. A BAZAN Group refinery in Haifa was hit during a broader Iranian missile attack on the area as a retaliation for Israeli attacks on South Pars gas facilities. Netanyahu insisted that "You can't make a revolution from the air" and that "there must be a ground component—I won't share with you all the options", implying that there was a potential for limited assault operations involving soldiers on the ground in Iran. The US began an aerial campaign against Iranian vessels and drones in the Strait of Hormuz in an effort to reopen it to international shipping.
Additionally, it was soon found that homopyrimidine and some purine-rich oligonucleotide are able form a stable H-DNA structure with the homopurine-homopyrimidine binding sequence-specific structures on the DNA duplexes.
Today the Catholic devotions to the Holy Face of Jesus are usually associated with the negative image of the Shroud of Turin, as first captured in Secondo Pia's 1898 photograph. However, these devotions predate Pia's image, having been established in 1844 by the Carmelite nun Marie of St Peter, based on depictions of Jesus before his crucifixion and associated with the tradition of the Veil of Veronica. This devotion was then promoted by a French Catholic layman, Leo Dupont, who became known as the "Apostle of the Holy Face". In 1851 Dupont formed the "Archconfraternity of the Holy Face" in the city of Tours. Pope Leo XIII approved the devotion to the Holy Face in 1885. The popular French Saint Thérèse of Lisieux took the name "Thérèse of the Child Jesus and the Holy Face" when she became a Discalced Carmelite in 1889. Saint Thérèse, who died in 1897, also helped to spread the devotion to the Holy Face before it became associated with Pia's photographic image of the Shroud of Turin. The modern devotion to the Holy Face centered on the negative photographic image from the Shroud of Turin derives principally from an Italian nun born in Milan, Maria Pierina De Micheli, who reported having visions of Jesus starting in 1936. Sister Maria Pierina designed a "Holy Face Medal", based on Secondo Pia's photographs. This medal was eventually approved for private devotion by Pope Pius XII.
Sources: en.wikipedia.org
=== Reproduction === Ginkgo biloba is dioecious, with separate sexes, some trees being female and others being male. Male plants produce small pollen cones with sporophylls, each bearing two microsporangia spirally arranged around a central axis. Sex conversion, wherein certain branches of a tree change sexes, has been observed. This phenomenon is difficult to research because of its rarity, as well as the practice of grafting female branches onto otherwise male trees that was common in 19th century Europe. Female plants do not produce cones. Two ovules are formed at the end of a stalk.
internal validation or cross-validation (actually, while extracting data, cross validation is a measure of model robustness, the more a model is robust (higher q2) the less data extraction perturb the original model); external validation by splitting the available data set into training set for model development and prediction set for model predictivity check; blind external validation by application of model on new external data and data randomization or Y-scrambling for verifying the absence of chance correlation between the response and the modeling descriptors. The success of any QSAR model depends on accuracy of the input data, selection of appropriate descriptors and statistical tools, and most importantly validation of the developed model. Validation is the process by which the reliability and relevance of a procedure are established for a specific purpose; for QSAR models validation must be mainly for robustness, prediction performances and applicability domain (AD) of the models. Some validation methodologies can be problematic. For example, leave one-out cross-validation generally leads to an overestimation of predictive capacity. Even with external validation, it is difficult to determine whether the selection of training and test sets was manipulated to maximize the predictive capacity of the model being published. Different aspects of validation of QSAR models that need attention include methods of selection of training set compounds, setting training set size and impact of variable selection for training set models for determining the quality of prediction.
=== 20 January === At least 11 people were killed by RSF shelling on the Abu Shouk IDP camp in El Fasher. A coalition of SAF and allied forces claimed to have repelled two RSF incursions from Libya in North Darfur near the tri-border area with Chad and Libya, killing a total of over 950 fighters, destroying 61 vehicles, and capturing 78 others that were equipped with advanced weaponry.
== References == Hall of Fame: Michael Laposata." Association for Diagnostics & Laboratory Medicine (ADLM). Retrieved 30 September 2026. "Association for Molecular Pathology Honors Michael Laposata with Champion for Innovation Award" (Press release). Association for Molecular Pathology. 2025. Retrieved 30 September 2026. Carried over from the current article: PBS Frontline, "If It's Not Abuse"; NBC News (13 December 2019); ProPublica (21 February 2012); NPR (28 June 2011). Federal District Court Vacates FDA's Laboratory Developed Tests Final Rule." FDA Law Blog. Hyman, Phelps & McNamara. April 2025. Retrieved 30 September 2026. Committee on Diagnostic Error in Health Care (2015). Balogh, Erin P.; Miller, Bryan T.; Ball, John R. (eds.). Improving Diagnosis in Health Care. Washington, DC: National Academies Press. doi:10.17226/21794. https://www.houstonchronicle.com/news/houston-texas/houston/article/Experts-say-the-state-should-add-safeguards-to-14902941.php https://www.thepathologist.com/issues/2025/articles/december/michael-laposata-receives-champion-for-innovation-award/ https://www.thepathologist.com/issues/2025/articles/november/peertopeer-ivan-damjanov-interviews-michael-laposata/ https://www.thepathologist.com/issues/2016/articles/jun/it-s-our-turn/ https://www.thepathologist.com/issues/2016/articles/jun/we-need-to-talk-pathologists-patients-and-diagnostic-errors-part-i/ https://www.thepathologist.com/issues/2016/articles/aug/it-s-our-turn-to-talk-pathologists-patients-and-diagnostic-errors-part-ii/ Laposata, M.; Connor, A. M.; Hicks, D. G.; Phillips, D. K. (1989).
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.